Nearly a quarter of patients with difficult-to-control type 2 diabetes have hypercortisolism, with even higher prevalence ...

Corcept sees 40% growth in 2025 revenue with promising trials, expanded patient base, and strong projections. Read my ...

Orforglipron, a daily GLP-1 receptor agonist pill, lowered HbA1c by up to 1.6% and body weight by 7.9% in a phase III trial ...

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of ...

The treatment strategy for congenital adrenal hyperplasia is burdensome and had not changed in more than 70 years until the ...

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic ...

The Food and Drug Administration (FDA) has approved Isturisa ® (osilodrostat) for the treatment of endogenous hypercortisolemia in adults with Cushing syndrome for whom surgery is not an option or has ...

More than 1800 women told us their stories of medical misogyny. Today we begin sharing those stories and building the case ...

Italian pharma major Recordati (RECI: MI) today announced that the US Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for Isturisa (osilodrostat) for the ...

Clinicians who are unaware of the pseudocondition may mistake elevated cortisol results for signs of true Cushing syndrome ...

Dr. Sistla completed her MBBS from Kamineni Institute of Medical Sciences in Telangana. Currently, she works as a leading ...

Patients are left confused and unsupported due to misdiagnosis and lack of awareness—even among doctors. That has to change,” she said. Cushing’s syndrome is a hormonal disorder caused by ...